Elpiscience Biopharma, Ltd. announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019, and another program.
Tag Archive for: collaboration
Bringing a drug to market is harder than ever, and manufacturers continue to navigate a complex road to get therapies to patients. On average, manufacturers spend more than $125 million over the three years leading up to launch, yet two-thirds of drugs fail to meet launch expectations.
Unlike their Big Pharma cousins, most start-ups just don’t have the same level of launch experience, and they also lack much of the key infrastructure taken for granted in the top ten organizations; and of course launch revenue is critical for a fledgling company.
Under a new collaborative research agreement, Astellas Pharma is turning to an interesting choice of partner to develop a novel antibody-drug conjugate platform for oncology therapeutics. Tuesday, the Tokyo-based biopharma announced a collaboration with tech giant Sony Corporation.
Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.
Moderna Inc. will collaborate with privately owned Life Edit Therapeutics Inc. under an agreement to discover and develop mRNA gene-editing therapies, the companies said on Wednesday.
ImmunoGen entered into a clinical collaboration deal with Gilead Sciences Friday to evaluate the safety and efficacy of two drugs that, when used in concert, have the potential to treat AML, a blood disorder biopharma has found challenging to target.
Vertex Pharmaceuticals agreed to a collaboration deal with the pre-clinical biotech Entrada Therapeutics, Thursday. The two companies announced a global partnership to develop intracellular Endosomal Escape Vehicle (EEV) therapeutics.
Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases, the companies announced Tuesday.
